Home

Health Care

Protecting Research and Research Participants

The public has a strong interest in protecting research and research participants. Federal policy must find the right balance in protecting participants while allowing critical research to continue.

Plant-Made Pharmaceuticals Background and Key Points
BioBytes: Forensics and Biotechnology

By utilizing DNA, scientists are able to create a genetic finger print that is unique to each individual to help find and prosecute crime suspects and identify remains.

BioBytes: Forensics and Biotechnology

By utilizing DNA, scientists are able to create a genetic finger print that is unique to each individual to help find and prosecute crime suspects and identify remains.

A Report on Alzheimer's Disease

Every 70 seconds someone develops Alzheimer's. By 2029 there will be 70 million retired baby boomers. If we dont find a way to treat the disease we are going to have a public health disaster.

Healing, Fueling, Feeding: How Biotechnology Is Enriching Your Life.

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

Ohio Biotech – Established and Growing

Ohio is a national leader in terms of both bioscience employment and establishments. In fact the industry accounts for about 15 percent of the state’s total economic output.

Honoring Industrial Innovation: BIO to Award 3rd Carver

Biotechnology might seem like a new science to many, but it has its roots in the work of some early big thinkers — among them George Washington Carver, arguably one of the world’s first industrial biotechnologists and the father of sustainable farming.

Rare Diseases: Can We Speed Treatments?
Battle Joined: Knowledge Pool Created to Fight Neglected Diseases

Scientific discoveries happen when researchers collaborate. That’s the thinking behind a partnership formed by GlaxoSmithKline and Alnylam Pharmaceuticals to share intellectual property (IP) and industrial know-how to develop new therapies to treat the world’s most neglected tropical diseases.

Millions Around World to Observe Rare Disease Day

On Sunday, Feb. 28, millions of people around the world will observe “World Rare Disease Day”. This is an annual event sponsored in the U.S. by the National Organization for Rare Disorders (NORD) and in Europe by the European Rare Disease Organisation (EURORDIS).

XENOTRANSPLANTATION: The Benefits and Risks of Special Organ Transplantation

Human organ transplantation is a relatively new field of medicine that is now facing a significant challenge.

From Biotech to Box Office: Film Draws from Real-Life Story

Real life sometimes looms larger than the characters and storylines of Hollywood.

Intellectual Property Pool: Podcast with BVGH, Alnylam and GlaxoSmithKline

GlaxoSmithKline and Alnylam Pharmaceuticals recently announced that BIO Ventures for Global Health will administer the Intellectual Property (IP) Pool to aid in the discovery and development of new treatments for neglected tropical diseases.

BioBytes: Genetically Engineered Animals

Disease resistant animals, environmentally friendly livestock, pharmaceuticals produced by goats - are these really possible?

Letters, Testimony & Comments

PBRER: BIO Comments on Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format
May 8 2013
  Dear Sir/Madam:   The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for...
Benefit-Risk: BIO Comments on FDA's Prescription Drug User Fee Act V Benefit-Risk Plan
May 7 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
Recombinant DNA: BIO Comments on WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology
April 19 2013
  The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the “WHO Guidelines on the Quality...
Immunogenicity: BIO Comments on Draft Guidance on Immunogenicity Assessment for Therapeutic Protein Products
April 12 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
Sunshine: BIO Files Comments on Estimated Burden of complying with Section 6002 of the Affordable Care Act (“the Sunshine Act”)
April 8 2013
BIO supports the goals of the Affordable Care Act (ACA) in providing greater transparency regarding financial relationships with...
More Letters, Testimony & Comments →

Press Releases

BIO Praises U.S. Senate for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act
February 28 2013
WASHINGTON, DC – February 28, 2013 –The Biotechnology Industry Organization (BIO) lauds the Senate for...
BIO Praises The House of Representatives for Approving H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act
January 25 2013
The Biotechnology Industry Organization lauds the House of Representatives for passing H.R. 307, the Pandemic and All...
PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement
October 1 2012
Washington, D.C. (October 1, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and...
IFPMA, BIO and WADA Advance Anti-Doping Collaboration with the Launch of 2 Fields 1 Goal Campaign
July 23 2012
Groups Issue Booklet to Help Biotechnology and Pharmaceutical Companies Identify Pipeline Medicines with Doping...
Supreme Court Affordable Care Act Ruling Must Now Lead to Implementation That Will Promote Innovation and Expand Access
June 28 2012
  Pleased to move forward on biosimilars pathway Washington, D.C. (June 28, 2012) –Biotechnology...
More Press Releases →